GlassScriptPhysician profile
Bethany Martin
NPI 1750999231
$16,994.95
in general payments reported to CMS, 2019-2025
84 companies · $2,857 in 2025
The $2,857 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,293 · 2022: $4,317 · 2023: $4,202 · 2024: $3,325 · 2025: $2,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,259.85 |
| Education | $124.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,356.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,214.00 | 2021-2025 | Enhertu, Lynparza |
| Janssen Biotech, INC. | $976.38 | 2021-2025 | Darzalex, Carvykti, Tecvayli |
| Celgene Corporation | $867.20 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $684.06 | 2021-2025 | Opdivo, Opdualag, Reblozyl |
| Eisai INC. | $624.58 | 2021-2025 | |
| Gilead Sciences, INC. | $580.09 | 2021-2025 | Trodelvy |
| Daiichi Sankyo INC. | $578.64 | 2021-2025 | Enhertu, Injectafer |
| Abbvie INC. | $553.12 | 2021-2025 | |
| Novocure INC. | $522.18 | 2023-2025 | Optune, Optune Lua (Novottf-200t) |
| Karyopharm Therapeutics INC. | $512.17 | 2021-2025 | Xpovio |
| Lilly USA, LLC | $483.28 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Genzyme Corporation | $423.64 | 2021-2025 | |
| Genentech USA, INC. | $393.45 | 2021-2025 | Tecentriq, Phesgo, Polivy |
| Seagen INC. | $387.07 | 2021-2023 | Tukysa, Adcetris, Padcev |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $351.48 | 2021-2023 | Kyprolis, Lumakras, Vectibix |
| Merck Sharp & Dohme LLC | $331.00 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $316.35 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Jazz Pharmaceuticals INC. | $284.31 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $279.77 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $264.59 | 2021-2023 | Tazverik |
| Incyte Corporation | $228.96 | 2021-2025 | Jakafi, Monjuvi, Niktimvo |
| Pfizer INC. | $205.27 | 2022-2025 | |
| Glaxosmithkline, LLC. | $203.47 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $186.19 | 2022-2024 | Alunbrig, Iclusig, Fruzaqla |
| Exelixis INC. | $178.20 | 2022-2025 | Cabometyx |
| Medtronic, INC. | $168.75 | 2025 | Osteocool Rf Ablation System |
| Sumitomo Pharma America, INC. | $167.67 | 2023-2025 | Orgovyx |
| Servier Pharmaceuticals LLC | $162.68 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $158.63 | 2022-2025 | Libtayo, Lynozyfic |
| Dendreon Pharmaceuticals LLC | $155.78 | 2021-2025 | Provenge |
| Kyowa Kirin, INC. | $148.85 | 2021-2024 | Poteligeo |
| Organon LLC | $148.11 | 2022-2024 | Ontruzant |
| Stemline Therapeutics INC. | $147.83 | 2023-2025 | Orserdu |
| Pharmaessentia USA Corporation | $126.59 | 2022-2024 | Besremi |
| G1 Therapeutics, INC. | $121.88 | 2022-2023 | Cosela |
| Janssen Scientific Affairs, LLC | $120.25 | 2022 | |
| Blueprint Medicines Corporation | $118.03 | 2021-2024 | Ayvakit |
| Tersera Therapeutics LLC | $115.98 | 2021-2023 | Xermelo |
| Pharmacyclics LLC, An Abbvie Company | $114.36 | 2021-2023 | Imbruvica |
| Aveo Pharmaceuticals, INC. | $112.11 | 2022-2025 | |
| Kite Pharma, INC. | $106.56 | 2021-2025 | Yescarta |
| Sobi, INC | $102.14 | 2023-2025 | |
| Taiho Oncology, INC. | $101.60 | 2021-2024 | |
| Recordati_rare_diseases_inc. | $97.76 | 2024-2025 | Enjaymo, Panhematin |
| Epizyme, INC. | $97.68 | 2021-2022 | |
| Beigene USA, INC. | $79.20 | 2021-2023 | Brukinsa |
| Acceleron Pharma, INC. | $75.95 | 2021 | |
| Springworks Therapeutics, INC. | $72.50 | 2024-2025 | Ogsiveo |
| Sun Pharmaceutical Industries INC. | $69.06 | 2021-2024 | Yonsa, Odomzo |
| Array Biopharma INC | $67.50 | 2022-2025 | Braftovi, Tukysa, Mektovi |
| Beone Medicines USA, INC. | $64.62 | 2025 | Brukinsa, Tevimbra |
| Apellis Pharmaceuticals, INC. | $63.42 | 2022-2024 | Empaveli |
| Pharmacosmos Therapeutics INC. | $63.34 | 2022-2024 | Cosela |
| Caris Mpi, INC. | $60.86 | 2025 | Mi Cancer Seek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.33 | 2024-2025 | Gilotrif |
| Mylan Institutional INC. | $55.95 | 2022-2023 | Fulphila, Ogivri |
| Puma Biotechnology, INC. | $53.72 | 2022-2023 | Nerlynx |
| Mirati Therapeutics, INC. | $48.72 | 2023-2024 | Krazati |
| Otsuka America Pharmaceutical, INC. | $44.25 | 2024-2025 | Rexulti |
| Genmab U.S., INC. | $43.63 | 2023-2024 | Tivdak |
| Astellas Pharma US INC | $39.42 | 2023 | Cresemba |
| Adaptive Biotechnologies Corporation | $38.04 | 2022 | |
| Genentech, INC. | $33.94 | 2023 | Lunsumio |
| Accord Healthcare, INC. | $30.85 | 2023-2024 | |
| Amag Pharmaceuticals, INC. | $26.98 | 2021 | |
| Pharmaand Gmbh | $24.42 | 2024 | Rubraca |
| Tolmar, INC. | $22.42 | 2025 | Jatenzo, Eligard |
| Amneal Pharmaceuticals LLC | $21.59 | 2023 | Neulasta, Neupogen, Avastin |
| Blue Earth Diagnostics | $21.54 | 2025 | Posluma |
| Emd Serono, INC. | $21.41 | 2024 | |
| Alexion Pharmaceuticals, INC. | $20.84 | 2024 | Ultomiris |
| Agios Pharmaceuticals, INC. | $20.66 | 2024 | Pyrukynd |
| Iovance Biotherapeutics, INC. | $19.15 | 2024 | Amtagvi |
| Menarini Silicon Biosystems, INC. | $18.54 | 2023 | Cellsearch |
| Dova Pharmaceuticals | $17.33 | 2021 | |
| Myovant Sciences INC. | $16.16 | 2022 | |
| Fresenius Kabi USA, LLC | $16.11 | 2025 | Stimufend |
| Teva Pharmaceuticals USA, INC. | $15.44 | 2023 | Truxima |
| Eusa Pharma (US) LLC | $15.31 | 2022 | |
| Cti Biopharma Corp. | $15.07 | 2022 | |
| Acrotech Biopharma INC. | $14.28 | 2021 | |
| Grifols USA, LLC | $13.10 | 2023 | Gamunex-C |
| Coherus Oncology, INC. | $12.72 | 2021 |
Drugs and devices associated with these payments
Enhertu $628Reblozyl $392Scemblix $382Xpovio $363Imbruvica $361Opdivo $303Optune $295Kisqali $292Epkinly $285Lenvima $273Optune Lua (Novottf-200t) $227Zepzelca $210Tavalisse $190Rezlidhia $190Pomalyst $186Jaypirca $179Darzalex $179Sarclisa $170Osteocool Rf Ablation System $169Orgovyx $168Venclexta $166Orserdu $148Verzenio $136Piqray $134Provenge $134Trodelvy $133Tazverik $119Cabometyx $119Cosela $115Tasigna $115Besremi $109Opdualag $108Ontruzant $107Libtayo $105Tecentriq $104Enjaymo $102Doptelet $102Carvykti $101Lunsumio $94.10Tukysa $93.47Fotivda $87.25Phesgo $84.12Jakafi $81.20Polivy $80.72Ojjaara $79.97Tecvayli $78.49Lynparza $77.77Rybrevant $77.51Ogsiveo $72.50Erleada $71.92Perjeta $67.56Krazati $66.53Vitrakvi $66.36Columvi $65.06Fabhalta $64.44Brukinsa $62.17Mi Cancer Seek $60.86Retevmo $59.44Nubeqa $56.61Tibsovo $54.92Alunbrig $51.62Poteligeo $48.08Kyprolis $47.74Empaveli $45.38Emrelis $44.28Rexulti $44.25Adcetris $44.12Tivdak $43.63Yescarta $43.43Odomzo $41.80Yonsa $41.80Cresemba $39.42Talvey $39.30Promacta $39.09Stivarga $38.74Kadcyla $38.69Herceptin $38.69Zejula $38.42Jemperli $38.42Monjuvi $36.93Oncaspar $36.47Idhifa $36.47Fulphila $35.06Ogivri $35.06Blenrep $34.61Lonsurf $33.97Inqovi $33.97Itovebi $33.36Pluvicto $32.61Jevtana $31.50Camcevi $30.85Ayvakit $30.41Wayrilz $29.23Tecentriq Hybreza $28.89Gilotrif $27.93Lumakras $25.52Rubraca $24.42Xermelo $24.36Ibrance $23.22Iclusig $22.97
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.